pembrolizumab
Selected indexed studies
- Pembrolizumab (Keytruda). (Hum Vaccin Immunother, 2016) [PMID:27398650]
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. (Ann Oncol, 2024) [PMID:38369015]
- Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. (J Clin Oncol, 2023) [PMID:36219809]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pembrolizumab (Keytruda). (2016) pubmed
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. (2024) pubmed
- Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. (2023) pubmed
- Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) pubmed
- Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. (2025) pubmed
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (2016) pubmed
- Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. (2025) pubmed
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. (2024) pubmed
- Pembrolizumab for the treatment of esophageal cancer. (2020) pubmed
- Pembrolizumab for the treatment of Hodgkin Lymphoma. (2020) pubmed